Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-2.03Last Year’s EPS
-2.52Same Quarter Last Year
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights meaningful operational and commercial progress — notably strong MNEXT Spike launch, substantial cost reductions (operating expenses down 30%, cost of sales down 41%, R&D down 31%), improved losses and a healthy cash balance — alongside multiple clinical and commercial catalysts (fully enrolled late‑stage trials, strategic partnerships, international filings). Major risks include the FDA refusal to file for the flu vaccine, continued net losses and cash runoff toward 2026, and reliance on event‑driven readouts and international approvals for growth. Overall, the company demonstrated strong execution and cost discipline but faces material regulatory and timing risks that temper near‑term visibility.Company Guidance
Revenue and Quarterly Performance
Total 2025 revenue of $1.9B; Q4 revenue $700M (U.S. $300M; international $400M). Full-year U.S. revenue $1.2B (≈62% of total) and international $700M (≈38%). Q4 came in at the higher end of guidance.
Commercial Launch Success — MNEXT Spike
MNEXT Spike approved and launched in the U.S. in 2025 with a strong debut: 24% share of the total U.S. retail COVID market and 34% share among adults 65+. Also approved in Canada and Australia, with further international approvals targeted.
Significant Cost Reductions and Efficiency Gains
Operating expenses down $2.2B or 30% for the year; Q4 operating expenses down 31% YoY. Cost of sales decreased 41% YoY to $868M; R&D down 31% to $3.1B; SG&A down 13% to $1.0B. Company exceeded its 2025 cost reduction plan by over $1B vs. original guidance.
Improved Loss Metrics and Strong Cash Position
Full-year net loss improved to $2.8B from $3.6B in 2024; loss per share improved to $7.26 from $9.28 (≈22% improvement). Ended 2025 with $8.1B in cash and investments (includes $600M credit draw); excluding the draw would have been $7.6B—above prior guidance ranges.
Clear 2026 Financial Framework and Return-to-Growth Guidance
Guidance of up to 10% revenue growth in 2026 (driven primarily by international markets), projected cash costs of $4.2B, GAAP operating expenses ~$4.9B, and year-end 2026 cash guidance of $5.5–6.0B. Revenue expected to be weighted ~15% H1 / ~85% H2.
Pipeline Progress and Clinical Milestones
Positive five-year phase 2 data for INT (individualized cancer therapy) in adjuvant melanoma showing ~50% reduction in relapse/death. Multiple late-stage oncology studies fully enrolled (adjuvant melanoma, adjuvant RCC, muscle invasive bladder). Norovirus phase 3 and PA registrational study fully enrolled — potential readouts in 2026.
Strategic Partnerships and Geographic Expansion
New five-year strategic supply agreement with Mexico; commercialization agreement with Recordati for propionic acidemia (PA) rare disease program; full-year contributions expected from local manufacturing agreements in the U.K., Canada, and Australia in 2026.
MRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 13, 2026 | $40.11 | $42.23 | +5.29% |
Nov 06, 2025 | $23.56 | $24.33 | +3.27% |
Aug 01, 2025 | $29.56 | $27.61 | -6.61% |
May 01, 2025 | $28.54 | $27.03 | -5.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Moderna (MRNA) report earnings?
Moderna (MRNA) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Moderna (MRNA) earnings time?
Moderna (MRNA) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRNA EPS forecast?
MRNA EPS forecast for the fiscal quarter 2026 (Q1) is -2.03.
